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ABSTRACT 
Tuberculosis (TB) is still a leading cause of morbidity and mortality among people 
living with HIV (PLHIV). The diagnosis of latent TB is required for the implementation 
of prophylactic therapy with isoniazid (PTI). However, low access to diagnosis of latent 
TB and non-adherence to PTI may hinder potential benefits of this essential intervention. 
In this study, we addressed the access and adherence to PTI in a cohort of PLHIV with 
positive tuberculin skin test (TST) in a reference HIV clinic in Sao Paulo, Brazil. We have 
also analyzed the occurrence of active TB over a median of 131 months after a positive TST 
among study participants. Our findings revealed that 88.3% of the 238 TST-positive patients 
had access to PTI, and 196 (93.3%) of those with access adhered to PTI. Active tuberculosis 
was diagnosed in three of the 196 TST-positive patients who adhered to PTI (1.5%; 95% 
confidence interval [CI] 0.3-4.4%), whereas seven cases were detected among 42 patients 
without access or who did not adhere to PTI (16.6%; 95% CI 7.0-31.3%). The apparent 
beneficial effect of PTI in our cohort is consistent with previous studies including PLHIV, 
and highlights the importance of reliably delivering each of the steps between screening for 
latent TB and provision of PTI.
KEYWORDS: Active tuberculosis. Adherence. HIV. Isoniazid preventive therapy. 
Prophylactic therapy. Tuberculin skin test. Tuberculin test. Tuberculosis.
INTRODUCTION
According to the World Health Organization (WHO) Global tuberculosis 
report 2019, tuberculosis (TB) is the leading cause of death from a single 
infectious agent, with estimated 1.2 million deaths among HIV-negative people 
and additional 251,000 deaths among people living with HIV (PLHIV) in 2018 
alone. HIV infection is a consistent risk factor for active TB, and PLHIV represent 
8.6% of all TB cases1. 
Brazil is one of the 30 countries with high TB burden listed by WHO, which 
collectively represent 87% of the global occurrence of the disease. In 2015, 
69,000 TB cases and 4,500 TB-related deaths were registered in Brazil, of which 
1,700 occurred among PLHIV. Sao Paulo State recorded more than 17,000 TB 
cases in the same year, of which 1,474 occurred among PLHIV2.
Asymptomatic or latent infection with Mycobacterium tuberculosis precedes the 
development of active TB. Prophylactic therapy with isoniazid (PTI) is a safe and 
effective intervention to prevent the development of active TB among patients with 
latent infection3,4. A positive tuberculin skin test (TST) and/or positive interferon-γ 
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release assay are the currently available tools for latent TB 
diagnosis in clinical settings5. 
Although previous studies have documented the 
beneficial impact of PTI among PLHIV6-10, barriers in the 
diagnosis of latent TB infection, in the implementation of 
PTI, and non-adherence to PTI may hinder potential benefits 
of this essential intervention11-14.
In this retrospective cohort study, we addressed the access 
and adherence to PTI in a cohort of PLHIV with positive TST. 
We have also analyzed the occurrence of active tuberculosis 
over a median 131 months after a positive TST, according 
to PTI uptake among study participants. 
METHODS 
Around 3,500 adult patients attending the HIV 
outpatient clinic at Hospital das Clinicas da Faculdade de 
Medicina da Universidade de Sao Paulo were screened to 
participate in the study. 
We included all patients undergoing a TST between 
February 2005 and December 2009 as part of routine care. 
Local guidelines recommend yearly TST to all PLHIV 
without a previously positive TST and without previous or 
current active TB15, regardless of CD4+ counts. The test 
was performed with an intradermal injection of 0.1 mL of 
the purified protein derivative (PPD-Rt-23, Statens Serum 
Institut, Copenhagen)16 on the anterior part of the left arm. 
A trained nurse measured the local reaction 72 h after TST 
administration17-19. All  patients with reactions ≥ 5mm were 
considered to have a positive TST result. 
We addressed the access to PTI among patients who 
had a positive TST using isoniazid prescription records as 
well as medical chart records of isoniazid use. PTI regimen 
prescribed in our institution consisted of 300 mg of isoniazid 
daily, for 180 days. Adherence to PTI was characterized 
using pharmacy records of isoniazid monthly dispensations 
and data from medical charts. Directly observed treatment is 
not used for PTI in our clinic. PTI was considered complete 
for the all patients receiving treatment for at least 180 
consecutive days.
Retrospective follow-up of clinical outcomes was 
performed for a median of 131 months (range 107-154) to 
identify cases of active TB. We used data from medical charts, 
pharmacy records for dispensation of active TB regimen, 
laboratory results, histopathology and radiology reports, 
and the TB surveillance system from Sao Paulo State; the 
adjudication of active TB was carried out by two independent 
infectious diseases specialists. Different data sources were 
linked using either the unique identifier assigned for each 
patient in the hospital system, or the patient’s name and date 
of birth in the case of the TB surveillance system.
We used descriptive statistics to present patients’ 
characteristics. To compare patients with or without access 
to PTI we used chi-squared test for categorical variables 
and the Wilcoxon Rank-Sum test for numerical variables. 
For all analyses, we used Stata 15.1 (StataCorp. College 
Station, TX: StataCorp LP) with a 0.05 significance level.
The Ethics Committee of Hospital das Clinicas da 
Faculdade de Medicina da Universidade de Sao Paulo 
approved the study (approval Nº 2.624.521) with exemption 
of the informed consent due to the retrospective design and 
data collection of the study. All the participants’ identifiable 
information were maintained confidential throughout the 
study.
 
RESULTS
Between February 2005 and December 2009, 3,260 TST 
were performed in 1,983 patients. Of those, 72 h reaction 
measurement was carried out for 2,878 tests, with an overall 
percentage of missing TST measurement appointment of 
11.7%. TST was positive (≥ 5mm) in 246 participants, 
representing 8.5% of the patients with available TST 
measurement. After the exclusion of six patients lost 
to follow-up, one patient transferred to another clinic 
and one patient who died due to TB-unrelated causes, 
238 TST-positive patients were retrieved for evaluation of 
PTI access and adherence.
Access and adherence to PTI
Demographic and clinical characteristics of the 238 
TST-positive patients according to access to PTI are 
shown in Table 1. Access to PTI was identified in 210 of 
238 TST-positive patients (88.2%). Groups were similar 
in regard to sex, age, race, education, proportion under 
antiretroviral treatment, proportion with undetectable HIV 
viral load and regarding CD4+ lymphocyte counts; however, 
patients with access to PTI had higher median CD4+ nadir 
(215 vs. 153, p=0.031) and were more likely to have a 
TST ≥10 mm (71 vs. 32%, p<0.001). 
Among the 28 TST-positive patients for whom no 
PTI was prescribed (11.8%), 21 (75.0%) had no clear 
justification for the missed prescription in medical charts. 
The remaining seven TST-positive patients without access to 
PTI had medical chart notes listing depression (two patients) 
and chronic liver disease (three patients) as reasons for 
the absence of PTI; in two additional cases the healthcare 
provider questioned the accuracy of the TST result. 
Among the 210 TST-positive patients who had access 
to PTI, 196 (93.3%) were considered adherent to PTI 
(Figure 1). Of the 14 patients who were non-adherent, eight 
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Table 1 - Demographic and clinical characteristics of the 238 tuberculin skin test-positive patients, according to access to prophylactic 
therapy with isoniazid.
Access to prophylactic isoniazid
p-valueYes  
N=210 
No  
N=28 
Male sex (%) 147 (70.0) 21 (75.0) 0.585
Age at TST (years) 42 46 0.196
Ethnicity (%)   
    White/Caucasian 166 (79.0) 25 (89.3) 
    Non-white/caucasian 40 (19.0) 3 (10.7) 0.434
    Not informed 4 (1.9)  -
Education (years)   
    0 3 (1.4) 0 
    ≤ 7 22 (10.5) 2 (7.1) 
    8 - 11 134 (63.8) 20 (71.4) 0.864
    ≥ 12 29 (13.8) 5 (17.9) 
    Missing 22 (10.5) 1 (3.6) 
Under antiretroviral therapy (%) 185 (88.1) 26 (92.9) 0.455
CD4+ count at TST (cells/mm3) 653 514 0.140
Nadir CD4+ count (cells/mm3) 215 153 0.031
Undetectable HIV viral load (%) 150 (71.4) 23 (82.1) 0.359
Coexisting comorbidity (%) 106 (50.5) 12 (42.9) 0.449
Concurrent medications (%) 110 (52.4) 18 (64.3) 0.235
Tuberculin skin test ≥ 10 mm (%) 150 (71.4) 9 (32.1) < 0.001
Numeric variables are presented as medians. Undetectable HIV viral load is defined as < 400 copies/mL.
Figure 1 - Overview of the study participants and their outcomes.
remained free of active TB during the follow-up period. 
The median time on PTI was 75 days (41.7% of total PTI 
treatment) for the eight non-adherent patients without active 
TB. Information on the reasons for PTI withdrawal was 
available for two patients: one reported gastrointestinal 
side-effects and the other simply refused PTI.
Active TB diagnosis during follow-up
We detected active TB in three of the 196 PTI-adherent 
patients (1.5%) after a median follow-up of 114 months. 
In contrast, six of the 14 patients who were non-adherent 
to PTI developed active TB after a median follow-up of 
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Table 2 - Detailed description of the 10 active tuberculosis cases identified in the cohort.
Case Age, Sex Ethnicity ART 
CD4+  
count  
(cells/mm3)
Undetectable 
HIV viral load 
under ART
TST 
(mm)
PTI  
access
PTI 
adherence
Time  
on PTI 
(days)
Time to TB 
(months)
TB presentation  
and clinical  
outcome
1 41, F Mixed Yes 511 Yes 15 Yes Yes 180 16
Pulmonary and urinary 
tract TB, treatment 
completed; cure
2 49, M Caucasian Yes 42 No 9 Yes Yes 180 114
Pulmonary and bone TB, 
poor retention, did not 
complete treatment
3 38, F Caucasian Yes 147 Yes 19 Yes Yes 180 132 Pulmonary TB, treatment 
completed; cure
4 58, M Caucasian Yes 271 No 6 Yes No 90 23 Pulmonary TB, treatment 
completed; cure
5 25, M Caucasian Yes 119 No 18 Yes No 90 53
Lymph node TB, poor 
retention, did not 
complete treatment
6 32, F Caucasian Yes 609 Yes 21 Yes No 30 95
Meningeal and urinary 
tract TB, treatment 
completed; cure
7 24, F Caucasian Yes 339 Yes 20 Yes No 90 117
Pulmonary and 
meningeal TB, treatment 
completed; death
8 71, M Black Yes 37 No 9 Yes No 60 121 Pulmonary TB, treatment 
completed; cure
9 42, M Caucasian Yes 447 Yes 19 Yes No 150 129 Miliary TB, treatment 
completed; cure
10 57, M Black Yes 550 Yes 15 No Not 
applicable 0 59
Ocular TB, treatment 
completed; cure
M = male; F = female; ART = antiretroviral therapy; TST = tuberculin skin test; PTI = prophylactic therapy with isoniazid; TB = tuberculosis; HIV viral 
load was considered undetectable when < 400 copies/mL
106 months post positive TST (42.9%). Of the 28 patients 
who failed to access PTI, one (3.6%) developed active TB 
after 59 months. 
A complete description of the access and adherence to 
PTI, as well as active TB development is presented in Figure 1, 
and a detailed description of active TB cases is provided in 
Table 2. All patients with active TB were under antiretroviral 
therapy, although only six of them had undetectable HIV 
viral load (< 400 copies/mL). In six patients, CD4 count 
was < 350/mm3. Respiratory tract was the single site of TB 
in only three cases; disseminated TB, affecting two or more 
organs was diagnosed in five cases; TB restricted to eyes and 
lymph nodes accounted for one case each. 
All except for one patient had access to PTI, however 
non-adherence was detected in six cases, including four 
patients with CD4 count < 350/mm3. Among the three 
patients adherent to PTI, two had very low CD4+ counts 
(147 and 42 cells/mm3), which may have predisposed to 
active TB despite PTI. Poor retention in TB treatment was 
observed for two patients. One patient with pulmonary and 
meningeal TB died three months after TB diagnosis, and 
the remaining seven patients were considered cured after 
TB treatment.
Effect of prophylactic therapy with isoniazid on the 
development of active tuberculosis among PLHIV 
with a positive TST
Overall, only three TB cases were diagnosed among 
196 TST-positive patients who adhered to PTI (1.5%; 
95% confidence interval [CI] 0.3-4.4%), whereas seven 
cases were detected among 42 patients without access or 
non-adherent to PTI (16.6%; 95% CI 7.0-31.3%; p<0.001). 
DISCUSSION
In this retrospective cohort, we showed that more than 
10% of PLHIV who had positive TST as part of routine care, 
failed to receive PTI in an academic HIV outpatient clinic in 
Sao Paulo, Brazil. Interestingly, participants with access to 
PTI had higher median CD4+ nadir (215 vs. 153, p=0.031). 
Access to PTI may have been facilitated for patients with 
better overall access to healthcare, who underwent HIV 
testing earlier in the course of infection. We have also found 
that participants with access to PTI were more likely to have 
a TST ≥10 mm (71 vs. 32%, p<0.001). It is plausible that 
providers were more persuaded to prescribe PTI for patients 
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with a TST ≥ 10 mm given that lower measurements might 
be due to previous BCG vaccination, routinely performed 
in Brazil.
Adherence to PTI was high (93.3%) among patients who 
received PTI. Although active TB was diagnosed in only 
10 cases (4.2%) after a median follow-up of 105 months, 
patients with access and adherence to PTI had lower 
occurrence of active TB when compared to patients without 
access or non-adherent to PTI (1.5%, 95% CI 0.3-4.4 vs. 
16.6%, 95% CI 7.0-31.3, respectively).
Yearly screening of latent TB infection is recommended 
by the Brazilian Ministry of Health20,21, and PTI is 
recommended for all PLHIV with a TST ≥ 5 mm. In settings 
with scarcity of TST, PTI is recommended for all PLHIV 
with CD4+ counts < 350, those with virological failure 
or who are not on antiretroviral therapy, and those with 
increased risk based on epidemiological characteristics15,22. 
It is also important to mention that antiretroviral treatment 
is available in the Brazilian public healthcare system for 
all PLHIV, and HIV clinics offer joint, free of charge care 
for patients with latent or active TB. The Brazilian Ministry 
of Health issues comprehensive and updated guidelines for 
TB management among PLHIV22. 
TST has important limitations. The yearly frequency 
of TST performance may fail to detect TB exposure 
between the measurements. Moreover, the measurement 
of TST result requires an additional consultation at the 
healthcare service, increasing the cost, complexity, and 
incurring in a higher percentage of missing results. 
In our cohort, 382 (11.7%) of 3,260 TST performed 
missed the return visit and could not be included in the 
study23,24. Finally, the shortage of supplies required to 
perform TST has been documented in several states of 
Brazil and have also been reported in a few studies25-27. 
One alternative diagnostic test to identify latent TB is 
the interferon-γ release assay, which detects the patient’s 
lymphocyte response to TB-specific antigens using 
a single blood sample. Cost-effectiveness studies are 
currently underway in Brazil to investigate the feasibility 
of implementation of this test. 
Our study had a few limitations. Only 1,983 patients 
underwent TST during the study period. The remaining 
1,500 PLHIV regularly followed in our clinic failed to 
perform TST because: i) They had a positive test in the 
past, with or without prior PTI; ii) They had previous or 
current TB; iii) They had contraindications to PTI; iv) The 
healthcare provider failed to request the test; v) The patient 
failed to perform the test despite a medical indication. 
Considering that the nursing providers in our institution 
routinely screen patients who are eligible for TST, we 
believe that failure of TST requesting was a rare event. 
In addition, most patients have been followed for several 
years and, in an endemic country such as Brazil, are likely 
to have had a positive TST in the past.
One strength of our study is the use of prospectively 
collected data from a large reference clinic in the Sao Paulo 
State, allowing the linkage of data from different sources.
Previous studies conducted in Africa and in Brazil showed 
lower rates of access and adherence to PTI compared to our 
study12,28,29. In the study conducted by Saraceni et al.30 in Rio 
de Janeiro, only 17 of 67 eligible PLHIV (25.4%) had access 
to PTI; adherence to PTI was 53% among Brazilian patients 
enrolled in general healthcare facilities31. Santos et al.32 
showed that 53 out of 66 eligible PLHIV had access to PTI 
(80.3%), but only 26 completed PTI (49.1%). In our own 
institution, a cross-sectional study conducted in 2005 showed 
that only 59% of eligible PLHIV had access to TST and 
only 55% of eligible patients had access to PTI11. This study 
prompted the initiation of a training and education program 
along with the establishment of routine screening of patients 
during every pre-consultation evaluation and consequently, 
the access and adherence to PTI have increased substantially 
in our institution.
Although the overall access and adherence to PTI were 
high in our cohort (88.2 and 93.3% respectively), only seven 
out of 28 patients (25%) included in our study who failed to 
access PTI had medical charts notes describing the reason 
why PTI was not prescribed. This highlights the need for 
continuous training among healthcare providers, even in an 
academic institution.
Other studies including PLHIV have addressed 
predictors of adherence to PTI among PLHIV. In a study 
conducted in urban Malawi, Thindwa et al.33 showed that 
lower CD4+ counts, PTI side effects and HIV WHO stages 
3 and 4 were associated with lower adherence to PTI. In 
Brazil, treatment intolerance and distance to the healthcare 
facility were identified as predictors of non-adherence to 
PTI among household contacts of TB patients34. In our 
study, since most patients were adherent to PTI, we could 
not explore the risk factors for PTI non-adherence. 
The apparent beneficial effect of PTI in our cohort 
is consistent with previous studies including PLHIV 
and underscores the importance of a reliable delivery of 
each step between screening of latent TB and provision 
of PTI. In a recent review, Alsdurf et al.35 described 
significant flaws at several steps in the cascade of latent TB 
diagnosis and treatment, including completion of testing, 
medical evaluation after testing, referral for treatment and 
completion of treatment. The high access and adherence to 
PTI observed in our clinic was achieved after education and 
treatment interventions that must be periodically repeated 
so as to attain the highest impact. However, 11.7% of 
Picone et al.
Rev Inst Med Trop São Paulo. 2020;62:e8Page 6 of 7
our patients missed the TST measurement appointment, 
revealing potential pitfalls in the cascade of latent TB 
diagnosis and treatment. Strategies to further improve 
access and adherence to PTI have been explored by several 
authors, including shorter duration regimens, use of digital 
technologies to improve adherence and retention in care, 
use of simplified treatment regimens or use of regimens 
with better tolerance36-38. In addition, access to PTI could 
be improved with the implementation of the interferon-γ 
release assay testing in settings with scarcity of TST or 
whenever an additional visit to the clinic to assess the 
TST result is not feasible39. The burden of TB-associated 
morbidity and mortality among PLHIV highlights the need 
for a comprehensive management of latent TB diagnosis 
and treatment.
REFERENCES
 1. World Health Organization. Global tuberculosis report 2019. 
Geneva: WHO; 2019.
 2. São Paulo. Secretaria de Estado da Saúde. Coordenadoria de 
Controle de Doenças. Centro de Vigilância Epidemiológica 
“Prof. Alexandre Vranjac”. Programa de Controle da 
Tuberculose do Estado de São Paulo. Plano estadual pela 
eliminação da tuberculose: 2018 a 2021. [cited 2020 Jan 7]. 
Available from: http://www.saude.sp.gov.br/resources/cve-
centro-de-vigilancia-epidemiologica/areas-de-vigilancia/
tuberculose/doc/tb17_plano_eliminacao.pdf
 3. Conde MB, Melo FA, Marques AM, Cardoso NC, Pinheiro VG, 
Dalcin PT, et al. III Diretrizes para Tuberculose da Sociedade 
Brasileira de Pneumologia e Tisiologia. J Bras Pneumol. 
2009;35:1018-48.
 4. Zenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der 
Werf MJ. Treatment of latent tuberculosis infection: an updated 
network meta-analysis. Ann Intern Med. 2017;167:248-55.
 5. World Health Organization. Latent tuberculosis infection: 
updated and consolidated guidelines for programmatic 
management. Geneva: WHO; 2018. [cited 2020 Jan 7]. 
Available from: https://apps.who.int/iris/bitstream/hand
le/10665/260233/9789241550239-eng.pdf
 6. Ayele HT, Mourik MS, Debray TP, Bonten MJ. Isoniazid 
prophylactic therapy for the prevention of tuberculosis in 
HIV infected adults: a systematic review and meta-analysis 
of randomized trials. PLoS One. 2015;10:e0142290.
 7. Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, 
et al. A trial of early antiretrovirals and isoniazid preventive 
therapy in Africa. N Engl J Med. 2015;373:808-22.
 8. Bruins WS, van Leth F. Effect of secondary preventive therapy 
on recurrence of tuberculosis in HIV-infected individuals: a 
systematic review. Infect Dis (Lond). 2017;49:161-9.
 9. Golub JE, Cohn S, Saraceni V, Cavalcante SC, Pacheco AG, 
Moulton LH, et al. Long-term protection from isoniazid 
preventive therapy for tuberculosis in HIV-infected patients 
in a medium-burden tuberculosis setting: the TB/HIV in Rio 
(THRio) study. Clin Infect Dis. 2015;60:639-45.
 10. Briggs MA, Emerson C, Modi S, Taylor NK, Date A. Use of 
isoniazid preventive therapy for tuberculosis prophylaxis 
among people living with HIV/AIDS: a review of the literature. 
J Acquir Immune Defic Syndr. 2015;68 Suppl 3:S297-305.
 11. Gutierrez EB, Gomes V, Picone CM, Suga H, Atomiya AN. Active 
tuberculosis and Mycobacterium tuberculosis latent infection 
in patients with HIV/AIDS. HIV Med. 2009;10:564-72.
 12. Durovni B, Cavalcante SC, Saraceni V, Vellozo V, Israel G, King 
BS, et al. The implementation of isoniazid preventive therapy 
in HIV clinics: the experience from the TB/HIV in Rio (THRio) 
study. AIDS. 2010;24 Suppl 5:S49-56.
 13. Eldred LJ, Churchyard G, Durovni B, Godfrey-Faussett P, Grant 
AD, Getahun H, et al. Isoniazid preventive therapy for HIV-
infected people: evidence to support implementation. AIDS. 
2010;24 Suppl 5:S1-3.
 14. Durovni B, Saraceni V, Moulton LH, Pacheco AG, Cavalcante SC, 
King BS, et al. Effect of improved tuberculosis screening and 
isoniazid preventive therapy on incidence of tuberculosis and 
death in patients with HIV in clinics in Rio de Janeiro, Brazil: 
a stepped wedge, cluster-randomised trial. Lancet Infect Dis. 
2013;13:852-8.
 15. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde.
Departamento de Vigilância, Prevenção e Controle das 
Infecções Sexualmente Transmissíveis, do HIV/AIDS e das 
Hepatites Virais. Protocolo clínico e diretrizes terapêuticas para 
manejo da infecção pelo HIV em adultos. Brasília: Ministério 
da Saúde; 2018. [cited 2020 Jan 7]. Available from: http://www.
aids.gov.br/pt-br/pub/2013/protocolo-clinico-e-diretrizes-
terapeuticas-para-manejo-da-infeccao-pelo-hiv-em-adultos
 16. Magnusson M, Bentzon MW. Preparation of purified tuberculin 
RT 23. Bull World Health Organ. 1958;19:829-43.
 17. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. 
Departamento de Vigilância Epidemiológica. Tratamento 
diretamente observado (TDO) da tuberculose na atenção 
básica: protocolo de enfermagem. Brasília: Ministério da 
Saúde; 2011. [cited 2020 Jan 7]. Available from: http://
bvsms.saude.gov.br/bvs/publicacoes/tratamento_diretamente_
observado_tuberculose.pdf
 18. Carneiro AJ, Andrade GN, Becker RS, Azevedo LB. Teste 
tuberculínico: diluição padronizada do PPD Rt 23 no Brasil. 
J Pneumol. 1986;12:21-7.
 19. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. 
Departamento de Vigilância das Doenças Transmissíveis. 
Técnicas de aplicação e leitura da prova tuberculínica. 
Brasília: Ministério da Saúde; 2014. [cited 2020 Jan 7]. 
Available from: http://bvsms.saude.gov.br/bvs/publicacoes/
tecnicas_aplicacao_leitura_prova_tuberculinica.pdf
Rev Inst Med Trop São Paulo. 2020;62:e8
Access and adherence to isoniazid preventive therapy and occurrence of active TB in a cohort of people living with HIV
Page 7 of 7
 20. Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, et 
al. Debunking the myths perpetuating low implementation of 
isoniazid preventive therapy amongst human immunodeficiency 
virus-infected persons. World J Virol. 2015;4:105-12.
 21. Brasil. Ministério da Saúde. Secretaria de Vigilância 
em Saúde. Brasil livre da tuberculose: evolução dos 
cenários epidemiológicos e operacionais da doença. Bol 
Epidemiol. 2019;50:1-18. [cited 2020 Jan 7]. Available 
from: http://portalarquivos2.saude.gov.br/images/pdf/2019/
marco/22/2019-009.pdf
 22. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. 
Departamento de Vigilância das Doenças Transmissíveis. 
Manual de recomendações para o controle da tuberculose no 
Brasil. 2ª ed. atual. Brasilia: Ministério da Saúde; 2019. [cited 
2020 Jan 7]. Available from: http://bvsms.saude.gov.br/bvs/
publicacoes/manual_recomendacoes_controle_tuberculose_
brasil_2_ed.pdf 
 23. Siqueira KZ, Mendonça SA, Penedo CC. Indicação da prova 
tuberculínica e infecção latente da tuberculose em HIV-
positivos, município de Blumenau, Estado de Santa Catarina, 
Brasil, 2004-2009. Epidemiol Serv Saude. 2012;21:635-44.
 24. Lester R, Hamilton R, Charalambous S, Dwadwa T, Chandler C, 
Churchyard GJ, et al. Barriers to implementation of isoniazid 
preventive therapy in HIV clinics: a qualitative study. AIDS. 
2010; 24 Suppl 5:S45-8.
 25. Sociedade Brasileira de Medicina Tropical. Brasil está há mais de um 
ano sem conseguir comprar testes para diagnosticar tuberculose 
latente. [cited 2020 Jan 7]. Available from: http://www.sbmt.
org.br/portal/brasil-esta-ha-mais-de-um-ano-sem-conseguir-
comprar-testes-para-diagnosticar-tuberculose-latente/
 26. Tebruegge M, Bogyi M, Soriano-Arandes A, Kampmann B. 
Shortage of purified protein derivative for tuberculosis testing. 
Lancet. 2014;384:2026.
 27. Centers for Disease Control and Prevention. Nationwide shortage 
of tuberculin skin test antigens: CDC recommendations for 
patient care and public health practice. MMWR Morb Mortal 
Wkly Rep. 2019;68:552-3.
 28. Little KM, Khundi M, Barnes GL, Ngwira LG, Nkhoma A, 
Makombe S, et al. Predictors of isoniazid preventive therapy 
completion among adults newly diagnosed with HIV in rural 
Malawi. Int J Tuberc Lung Dis. 2018;22:371-7.
 29. Ayele HT, van Mourik MS, Bonten MJ. Predictors of adherence 
to isoniazid preventive therapy in people living with HIV in 
Ethiopia. Int J Tuberc Lung Dis. 2016;20:1342-7.
 30. Saraceni V, Pacheco AG, Golub JE, Vellozo V, Rei BS, Cavalcante 
SC, et al. Physician adherence to guidelines for tuberculosis 
and HIV care in Rio de Janeiro, Brazil. Braz J Infect Dis. 
2011;15:249-52.
 31. Trajman A, Long R, Zylberberg D, Dion M, Al-Otaibi B, Menzies 
D. Factors associated with treatment adherence in a randomised 
trial of latent tuberculosis infection treatment. Int J Tuberc 
Lung Dis. 2010;14:551-9.
 32. Santos DT, Garcia MC, Costa AA, Pieri FM, Meier DA, Albanese 
SP, et al. Infecção latente por tuberculose entre pessoas com 
HIV/AIDS, fatores associados e progressão para doença 
ativa em município no Sul do Brasil. Cad Saude Publica. 
2017;33:e00050916.
 33. Thindwa D, MacPherson P, Choko AT, Khundi M, Sambakunsi 
R, Ngwira LG, et al. Completion of isoniazid preventive 
therapy among human immunodeficiency virus positive adults 
in urban Malawi. Int J Tuberc Lung Dis. 2018;22:273-9.
 34. Machado Jr A, Finkmoore B, Emodi K, Takenami I, Barbosa T, 
Tavares M, et al. Risk factors for failure to complete a course 
of latent tuberculosis infection treatment in Salvador, Brazil. 
Int J Tuberc Lung Dis. 2009;13:719-25.
 35. Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The 
cascade of care in diagnosis and treatment of latent tuberculosis 
infection: a systematic review and meta-analysis. Lancet Infect 
Dis. 2016;16:1269-78.
 36. Nsengiyumva N, Mappin-Kasirer B, Oxlade O, Bastos M, Trajman 
A, Falzon D, et al. Evaluating the potential costs and impact of 
digital health technologies for tuberculosis treatment support. 
Eur Respir J. 2018;52:1801363.
 37. Daher A, Pitta L, Santos T, Barreira D, Pinto D. Using a single 
tablet daily to treat latent tuberculosis infection in Brazil: 
bioequivalence of two different isoniazid formulations 
(300 mg and 100 mg) demonstrated by a sensitive and rapid 
high-performance liquid chromatography-tandem mass 
spectrometry method in a randomised, crossover study. Mem 
Inst Oswaldo Cruz. 2015; 110:543-50.
 38. Vidal JS, Silva MT, Sanchez MN. Rifapentine for latent 
tuberculosis infection treatment in the general population and 
human immunodeficiency virus-positive patients: summary of 
evidence. Rev Soc Bras Med Trop. 2015;48:507-13.
 39. Kussen GM, Dalla-Costa LM, Rossoni A, Raboni SM. Interferon-
gamma release assay versus tuberculin skin test for latent 
tuberculosis infection among HIV patients in Brazil. Braz J 
Infect Dis. 2016;20:69-75.
